Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Dual endothelin receptor blockade: advances in pulmonary disease Source: Annual Congress 2008 - Mastering pulmonary arterial hypertension: defined by evidence - enhanced by experience Year: 2008
Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004
Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008
Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Endothelin and endothelin receptor A in lymphangioleiomyomatosis Source: Annual Congress 2007 - Biomarkers in inflammatory lung disease Year: 2007
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Inhalation of endothelin receptor blockers in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Expression of endothelin receptor subtypes in different pulmonary tumours Source: Eur Respir J 2005; 26: Suppl. 49, 456s Year: 2005
Evaluation of a selective 5-hydroxytryptamine 2B receptor antagonist designed to alter the fibrotic process Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020